Insights on the Betahistine Market to 2028 | Industry Statistics, Emerging Demands, Forecast to 2028

 

The global betahistine market is expected to grow at a CAGR of 3.2% during the forecast period (2022-2028). An estimated one in 1,000 people in the UK have Ménière’s disease, as per the National Institute for Health and Care Research. Betahistine orphan drug status for the treatment of PWS-linked obesity is also supporting to propel the market growth. According to the Hearing Health Foundation, approximately 45,000 to 60,000 cases of Ménière’s Disease are diagnosed each year. According to Oxford University Press research, vertigo affects about one in every three adults every year. The prognosis of the disease is initially unilateral and then progresses to bilateral; 15% of patients report clinical manifestations in both ears later in life; the onset age is 20 to 50 years of age; and it affects both men and women equally. 

Some of the key players profiled in the study are Auro Pharma, Inc., Sanis Health, Inc., and Grünenthal, among others. 

Betahistine Market Segmentation:

By Type 

• 8mg
• 16mg
• 24mg
• Others

By Application 

• Ménière’s Disease 
• Benign Paroxysmal Positional Vertigo
• PWS-linked Obesity 
• Others

Geographic Coverage

• North America Market Size and/or Volume
• Latin America Market Size and/or Volume
• Europe Market Size and/or Volume
• Asia-Pacific Market Size and/or Volume
• Rest of the world Market Size and/or Volume

Key questions answered in this report:

• What is the size of the Betahistine market and what is its expected growth rate?
• What are the primary driving factors that push the Betahistine Market forward?
• What are the Betahistine Industry’s top companies?
• What are the different categories that the Betahistine Market caters to?
• What will be the fastest-growing segment or region?
• In the value chain, what role do essential players play?
• What is the procedure for getting a free copy of the Betahistine Market sample report and company profiles?